## SEC Form 4

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

I

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	 <b>JT OF CHANGES IN BENEFICIAL OWI</b> pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	
1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol	5. Relatio

### D

	000					
OMB Number:	3235-0287					
Estimated average b	urden					
hours per response:	0.5					

1. Name and Address of Reporting Person <sup>*</sup> STARR KEVIN P (Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)			er Name <b>and</b> Ticke Therapeutics			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
SIARR KEV	<u>IIN P</u>			<u> </u>	<u>,</u> [ 01		X	Director	Х	10% C	wner	
C/O SAGE THE	RAPEUTIC	( )	3. Date 05/28	e of Earliest Transac /2015	ction (Month/D	ay/Year)		Officer (give title below)		Other below)	(specify	
215 FIRST STR	EET		4. If Ai	mendment, Date of	Original Filed (	(Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable					
·	MA	02142					Line)	Form filed by On Form filed by Mo Person	•	0		
(City)	(State)	(Zip)										
		Table I - Noi	n-Derivative S	ecurities Acq	uired, Disp	osed of, or Benef	cially	Owned				
1 Title of Coourity	(In a tr. 2)		2 Transaction	24 Deemed	2	4 Securities Acquired (A	) or	E Amount of	6.000	orchin	7 Noturo	

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4 and			Securities Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(1150.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(5-;	,		,		,,			, ,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		Expiration Da	6. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to buy)	\$73.13	05/28/2015		A		13,922		(1)	05/28/2025	Common Stock	13,922	\$73.13	13,922	D	

**Explanation of Responses:** 

1. The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in full on May 28, 2016, subject to continued service through such date.

#### **Remarks:**

#### /s/ Laurie Burlingame, as Attorney-in-Fact for Kevin P. <u>Starr</u>

05/29/2015

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.